Review

rna seq data analyses (Novogene)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Novogene rna seq data analyses
$Generating a humanized stroma PDX (HS-PDX). A Tumor growth curves (i–iii) and (iv) summary of relative final tumor volumes of HS-PDXs with the indicate EC (combination iHUVEC/iHDMEC or EPC sources. TC + CA-MSC in the absence or presence of human EC (TC + CA-MSC; n = 6) (iHDMEC + iHUVEC) and Pt. EC/EPC (TC + CA-MSC + EC/EPC; n = 7). Tumor volumes in A (iv) are normalized TC + CA-MSC alone at 100%. B Representative IF evaluation of human tumor vascular antigen CD31 (red) in PDXs with the indicated EC/EPC sources. 4′,6-diamidino-2-phenylindole (DAPI; blue) was used to label cell nuclei. C IF evaluation of a tumor-specific vascular marker EGFL6 (red). Cell nuclei were counterstained with DAPI (blue). D <t>RNA-Seq-based</t> relative mRNA expression for two patient PDXs without and with the addition of human endothelial cells. E Growth curves for standard PDX and HS-PDX, derived from a patient with platinum refractory ovarian cancer, treated with carboplatin (blue arrows indicate timing of carboplatin administration ( n = 4–7/treatment group). Tumor volumes are internally normalized to the initial measurement for each tumor (~ 100 mm 3 ). Abbreviations : CA-MSC, cancer-associated mesenchymal stem cells; EC, endothelial cells; EPC, endothelial progenitor cells; iHDMEC, immortalized human dermal microvascular endothelial cells; iHUVEC, immortalized human umbilical vein endothelial cells; PDX, patient-derived xenograft; P0 and P1, passage 0 and passage 1. The first generation of PDX is denoted P0, and P0 is subsequently passaged to second generation (P1); Pt., patient; TC, tumor cells. * p < 0.05, ** p < 0.01, *** p < 0.001. Scale bars in B and C are 20 µm$
Rna Seq Data Analyses, supplied by Novogene, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rna seq data analyses/product/Novogene
Average 86 stars, based on 1 article reviews

rna seq data analyses - by Bioz Stars, 2026-05

86/100 stars

Images

1) Product Images from "A novel humanized immune stroma PDX cancer model for therapeutic studies"

Article Title: A novel humanized immune stroma PDX cancer model for therapeutic studies

Journal: Cancer Immunology, Immunotherapy : CII

doi: 10.1007/s00262-026-04349-4

$Generating a humanized stroma PDX (HS-PDX). A Tumor growth curves (i–iii) and (iv) summary of relative final tumor volumes of HS-PDXs with the indicate EC (combination iHUVEC/iHDMEC or EPC sources. TC + CA-MSC in the absence or presence of human EC (TC + CA-MSC; n = 6) (iHDMEC + iHUVEC) and Pt. EC/EPC (TC + CA-MSC + EC/EPC; n = 7). Tumor volumes in A (iv) are normalized TC + CA-MSC alone at 100%. B Representative IF evaluation of human tumor vascular antigen CD31 (red) in PDXs with the indicated EC/EPC sources. 4′,6-diamidino-2-phenylindole (DAPI; blue) was used to label cell nuclei. C IF evaluation of a tumor-specific vascular marker EGFL6 (red). Cell nuclei were counterstained with DAPI (blue). D RNA-Seq-based relative mRNA expression for two patient PDXs without and with the addition of human endothelial cells. E Growth curves for standard PDX and HS-PDX, derived from a patient with platinum refractory ovarian cancer, treated with carboplatin (blue arrows indicate timing of carboplatin administration ( n = 4–7/treatment group). Tumor volumes are internally normalized to the initial measurement for each tumor (~ 100 mm 3 ). Abbreviations : CA-MSC, cancer-associated mesenchymal stem cells; EC, endothelial cells; EPC, endothelial progenitor cells; iHDMEC, immortalized human dermal microvascular endothelial cells; iHUVEC, immortalized human umbilical vein endothelial cells; PDX, patient-derived xenograft; P0 and P1, passage 0 and passage 1. The first generation of PDX is denoted P0, and P0 is subsequently passaged to second generation (P1); Pt., patient; TC, tumor cells. * p < 0.05, ** p < 0.01, *** p < 0.001. Scale bars in B and C are 20 µm$
Figure Legend Snippet: Generating a humanized stroma PDX (HS-PDX). A Tumor growth curves (i–iii) and (iv) summary of relative final tumor volumes of HS-PDXs with the indicate EC (combination iHUVEC/iHDMEC or EPC sources. TC + CA-MSC in the absence or presence of human EC (TC + CA-MSC; n = 6) (iHDMEC + iHUVEC) and Pt. EC/EPC (TC + CA-MSC + EC/EPC; n = 7). Tumor volumes in A (iv) are normalized TC + CA-MSC alone at 100%. B Representative IF evaluation of human tumor vascular antigen CD31 (red) in PDXs with the indicated EC/EPC sources. 4′,6-diamidino-2-phenylindole (DAPI; blue) was used to label cell nuclei. C IF evaluation of a tumor-specific vascular marker EGFL6 (red). Cell nuclei were counterstained with DAPI (blue). D RNA-Seq-based relative mRNA expression for two patient PDXs without and with the addition of human endothelial cells. E Growth curves for standard PDX and HS-PDX, derived from a patient with platinum refractory ovarian cancer, treated with carboplatin (blue arrows indicate timing of carboplatin administration ( n = 4–7/treatment group). Tumor volumes are internally normalized to the initial measurement for each tumor (~ 100 mm 3 ). Abbreviations : CA-MSC, cancer-associated mesenchymal stem cells; EC, endothelial cells; EPC, endothelial progenitor cells; iHDMEC, immortalized human dermal microvascular endothelial cells; iHUVEC, immortalized human umbilical vein endothelial cells; PDX, patient-derived xenograft; P0 and P1, passage 0 and passage 1. The first generation of PDX is denoted P0, and P0 is subsequently passaged to second generation (P1); Pt., patient; TC, tumor cells. * p < 0.05, ** p < 0.01, *** p < 0.001. Scale bars in B and C are 20 µm

Techniques Used: Marker, RNA Sequencing, Expressing, Derivative Assay

Identifying the optimal humanized bone marrow mouse type for the humanized immune stroma PDX (HIS-PDX). PDX models established in immunodeficient NSG, humanized HuNSG-SGM3 and humanized BLT mice were named as NSG-PDX, HuSGM3-PDX and BLT-PDX models, respectively. A-C RNA-seq-based mRNA analysis of the indicated lymphocyte ( A ), myeloid cell ( B ) and NK cell ( C ) markers genes in NSG-PDX, HuSGM3-PDX and BLT-PDX tumors. Expression is normalized using the expression in matched primary patient-derived tumor. D IF for human CD3, CD8, CD14 and CD163 evaluating tumor immune infiltrates in the indicated PDX tumor models. Cell nuclei were counterstained with DAPI (blue). Scale bars, 20 µm

Figure Legend Snippet: Identifying the optimal humanized bone marrow mouse type for the humanized immune stroma PDX (HIS-PDX). PDX models established in immunodeficient NSG, humanized HuNSG-SGM3 and humanized BLT mice were named as NSG-PDX, HuSGM3-PDX and BLT-PDX models, respectively. A-C RNA-seq-based mRNA analysis of the indicated lymphocyte ( A ), myeloid cell ( B ) and NK cell ( C ) markers genes in NSG-PDX, HuSGM3-PDX and BLT-PDX tumors. Expression is normalized using the expression in matched primary patient-derived tumor. D IF for human CD3, CD8, CD14 and CD163 evaluating tumor immune infiltrates in the indicated PDX tumor models. Cell nuclei were counterstained with DAPI (blue). Scale bars, 20 µm

Techniques Used: RNA Sequencing, Expressing, Derivative Assay

Analysis of complete humanized immune stroma PDX (HIS-PDX). HIS-PDX were created by co-engraftment of PDX TC, CA-MSC and EC (iHUVEC + iHDMEC). A IF for alpha smooth muscle actin (αSMA; red), and human-specific mitochondrial antigen (hMitoc; green) or pan-cytokeratin (PanCK; green) to label tumor cells in standard and HIS-PDX. Cell nuclei were counterstained with DAPI (blue) ( n = 3). B Hematoxylin and eosin (H&E) staining for a cell line-derived xenograft, standard PDX, humanized immune stroma PDX (HIS-PDX) and matched patient’s primary tumor ( n = 3). C RNA-seq derived heat map for stromal and immune gene expression in solid tumor-derived standard PDXs (StndPDX), HIS-PDX and patient primary tumor ( n = 3). D Total gene expression correlation between primary human tumor and primary tumor-derived HIS-PDX for patient 1 and patient 4. Scale bars in ( A ), 40 µm; scale bars in ( B ), 100 µm

Figure Legend Snippet: Analysis of complete humanized immune stroma PDX (HIS-PDX). HIS-PDX were created by co-engraftment of PDX TC, CA-MSC and EC (iHUVEC + iHDMEC). A IF for alpha smooth muscle actin (αSMA; red), and human-specific mitochondrial antigen (hMitoc; green) or pan-cytokeratin (PanCK; green) to label tumor cells in standard and HIS-PDX. Cell nuclei were counterstained with DAPI (blue) ( n = 3). B Hematoxylin and eosin (H&E) staining for a cell line-derived xenograft, standard PDX, humanized immune stroma PDX (HIS-PDX) and matched patient’s primary tumor ( n = 3). C RNA-seq derived heat map for stromal and immune gene expression in solid tumor-derived standard PDXs (StndPDX), HIS-PDX and patient primary tumor ( n = 3). D Total gene expression correlation between primary human tumor and primary tumor-derived HIS-PDX for patient 1 and patient 4. Scale bars in ( A ), 40 µm; scale bars in ( B ), 100 µm

Techniques Used: Staining, Derivative Assay, RNA Sequencing, Gene Expression

Similar Products

Image Search Results

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: A novel humanized immune stroma PDX cancer model for therapeutic studies

doi: 10.1007/s00262-026-04349-4

Figure Lengend Snippet: Generating a humanized stroma PDX (HS-PDX). A Tumor growth curves (i–iii) and (iv) summary of relative final tumor volumes of HS-PDXs with the indicate EC (combination iHUVEC/iHDMEC or EPC sources. TC + CA-MSC in the absence or presence of human EC (TC + CA-MSC; n = 6) (iHDMEC + iHUVEC) and Pt. EC/EPC (TC + CA-MSC + EC/EPC; n = 7). Tumor volumes in A (iv) are normalized TC + CA-MSC alone at 100%. B Representative IF evaluation of human tumor vascular antigen CD31 (red) in PDXs with the indicated EC/EPC sources. 4′,6-diamidino-2-phenylindole (DAPI; blue) was used to label cell nuclei. C IF evaluation of a tumor-specific vascular marker EGFL6 (red). Cell nuclei were counterstained with DAPI (blue). D RNA-Seq-based relative mRNA expression for two patient PDXs without and with the addition of human endothelial cells. E Growth curves for standard PDX and HS-PDX, derived from a patient with platinum refractory ovarian cancer, treated with carboplatin (blue arrows indicate timing of carboplatin administration ( n = 4–7/treatment group). Tumor volumes are internally normalized to the initial measurement for each tumor (~ 100 mm 3 ). Abbreviations : CA-MSC, cancer-associated mesenchymal stem cells; EC, endothelial cells; EPC, endothelial progenitor cells; iHDMEC, immortalized human dermal microvascular endothelial cells; iHUVEC, immortalized human umbilical vein endothelial cells; PDX, patient-derived xenograft; P0 and P1, passage 0 and passage 1. The first generation of PDX is denoted P0, and P0 is subsequently passaged to second generation (P1); Pt., patient; TC, tumor cells. * p < 0.05, ** p < 0.01, *** p < 0.001. Scale bars in B and C are 20 µm

Article Snippet: RNA-seq data analyses were performed by Novogene and Dr. Hui Shen’s research group.

Techniques: Marker, RNA Sequencing, Expressing, Derivative Assay

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: A novel humanized immune stroma PDX cancer model for therapeutic studies

doi: 10.1007/s00262-026-04349-4

Figure Lengend Snippet: Identifying the optimal humanized bone marrow mouse type for the humanized immune stroma PDX (HIS-PDX). PDX models established in immunodeficient NSG, humanized HuNSG-SGM3 and humanized BLT mice were named as NSG-PDX, HuSGM3-PDX and BLT-PDX models, respectively. A-C RNA-seq-based mRNA analysis of the indicated lymphocyte ( A ), myeloid cell ( B ) and NK cell ( C ) markers genes in NSG-PDX, HuSGM3-PDX and BLT-PDX tumors. Expression is normalized using the expression in matched primary patient-derived tumor. D IF for human CD3, CD8, CD14 and CD163 evaluating tumor immune infiltrates in the indicated PDX tumor models. Cell nuclei were counterstained with DAPI (blue). Scale bars, 20 µm

Article Snippet: RNA-seq data analyses were performed by Novogene and Dr. Hui Shen’s research group.

Techniques: RNA Sequencing, Expressing, Derivative Assay

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: A novel humanized immune stroma PDX cancer model for therapeutic studies

doi: 10.1007/s00262-026-04349-4

Figure Lengend Snippet: Analysis of complete humanized immune stroma PDX (HIS-PDX). HIS-PDX were created by co-engraftment of PDX TC, CA-MSC and EC (iHUVEC + iHDMEC). A IF for alpha smooth muscle actin (αSMA; red), and human-specific mitochondrial antigen (hMitoc; green) or pan-cytokeratin (PanCK; green) to label tumor cells in standard and HIS-PDX. Cell nuclei were counterstained with DAPI (blue) ( n = 3). B Hematoxylin and eosin (H&E) staining for a cell line-derived xenograft, standard PDX, humanized immune stroma PDX (HIS-PDX) and matched patient’s primary tumor ( n = 3). C RNA-seq derived heat map for stromal and immune gene expression in solid tumor-derived standard PDXs (StndPDX), HIS-PDX and patient primary tumor ( n = 3). D Total gene expression correlation between primary human tumor and primary tumor-derived HIS-PDX for patient 1 and patient 4. Scale bars in ( A ), 40 µm; scale bars in ( B ), 100 µm

Article Snippet: RNA-seq data analyses were performed by Novogene and Dr. Hui Shen’s research group.

Techniques: Staining, Derivative Assay, RNA Sequencing, Gene Expression